The efficacy of low-power cumulative high-intensity focused ultrasound treatment for recurrent desmoid tumor

Cancer Med. 2022 May;11(10):2079-2084. doi: 10.1002/cam4.4573. Epub 2022 Mar 11.

Abstract

Background: Desmoid tumors are rare neoplasms that are locally invasive. However, optimal treatment strategies for recurrent desmoid tumors remain controversial. High-intensity focused ultrasound (HIFU) has been reported as a noninvasive modality for treating recurrent desmoid tumors. However, its efficacy against massive desmoid tumors or those with complex anatomies remains unclear.

Methods: We developed a new therapeutic strategy called low-power cumulative HIFU and applied it to treat recurrent desmoid tumors.

Results: We retrospectively collected data from 91 patients with recurrent desmoid tumors who underwent low-power cumulative HIFU treatment after surgical treatment failure. The mean ablation proportion of the HIFU treatment was 69.5%, and the objective response rate was 47.3%. The 5-year estimated progression-free survival rate for these patients was 69.3%.

Conclusion: Low-power cumulative HIFU treatment could achieve significant efficacy and long-term control of recurrent desmoid tumors.

Keywords: aggressive fibromatosis; desmoid tumor; efficacy; high-intensity focused ultrasound; low-power cumulative HIFU.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Data Collection
  • Fibromatosis, Aggressive* / diagnostic imaging
  • Fibromatosis, Aggressive* / pathology
  • Fibromatosis, Aggressive* / therapy
  • High-Intensity Focused Ultrasound Ablation*
  • Humans
  • Progression-Free Survival
  • Retrospective Studies
  • Treatment Outcome